Using smartphone and wearable data plus AI-guided online CBT to personalize depression care
Official title: Integrating Digital Phenotypes and AI-Driven Cognitive-Behavioral Therapy: Advancing Precision Medicine in Depression Through Digital Medicine
Run by National Science and Technology Council, Taiwan · NCT07500714 · Data updated 2026-11-12
This project will try combining real-time smartphone and wearable monitoring with AI-driven online cognitive-behavioral therapy to personalize treatment for adults (18–75) with major depressive disorder in Taiwan.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | National Science and Technology Council, Taiwan Government |
| Locations | 1 site (Taichung, Taichung) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | June 2027 |
| Study ends | July 2027 |
| Registry record updated | March 30, 2026 |
| Trial ID | NCT07500714 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with DSM-5 major depressive disorder, HAMD-21 > 17, stable psychiatric treatment for at least four weeks, capacity to consent, and ability to use a smartphone and attend the Taichung site are ideal candidates.
✕Probably not a fit
Patients with marked to extreme illness severity (high CGI-S), psychotic or bipolar disorders, recent substance use disorder, active suicidal ideation, or unstable medical illness are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants will provide passive and active digital phenotyping data (behavioral and physiological signals) via smartphones and wearables while receiving either AI-driven internet cognitive-behavioral therapy or a sham internet intervention. The platform will link dynamic, real-time markers to symptom changes to refine diagnostic classifications and guide individualized therapeutic recommendations. Eligible participants are adults with DSM-5 major depressive disorder and a HAMD-21 score above 17 who have had no recent changes in psychiatric treatment. The study is conducted at the Mind Body Interface Research Center in Taichung and aims to integrate data-driven diagnostics with personalized digital treatment pathways.
Why it matters
Potential benefit: If successful, the approach could speed up matching patients to more effective, personalized treatments and reduce the need for frequent in-person visits.
How similar studies have gone: Previous work has shown promising results for internet CBT and for digital phenotyping separately, but combining real-time digital markers with AI-driven individualized CBT is relatively novel and less well tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) Aged 18-75 years * Diagnosis of major depressive disorder disorder (Based on Diagnostic Statistical Manual 5) * 21-item Hamilton Depression Scale (HAMD21)\>17 * No changes in current psychiatric treatment for depression (e.g., no treatment, antidepressant medication, psychotherapy, or non-invasive brain stimulation) within the past four weeks, and * Full competency to understand the study details and provide written informed consent Exclusion Criteria: * Scores of 5 ( Markedly ill), 6,(Severely ill), and 7 (Among the most extremely ill) according to the Clinical Global Impression Scale-Severity (CGI-S) * Psychotic disorders, bipolar affective disorder, a substance use disorders in the past 6 months, active suicidal or homicidal ideation (per assessment or HAMD\>3) * Unstable or active medical illness.
Where it's running
-
Mind Body Interface Research Center (MBI Lab & Care)
Taichung, Taichung, Taiwan Recruiting
Study contacts
- Study coordinator: Kuan-Pin Su, MD, PhD.
- Email: cobol@cmu.edu.tw
- Phone: 04-22361230
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding how the orbitofrontal cortex guides approach vs. avoidance in depression
This study tests how different parts of the orbitofrontal cortex influence whether people pursue rewards or risk loss, and whether this pattern is altered in Major Depressive Disorder.
-
Health education program to help depression in older adults and caregivers in Ho Chi Minh City
A community-based education program for people 60+ and their caregivers is being tested to see if it can lower depression and improve quality of life compared with standard care.
-
Prucalopride for low mood: testing a 5-HT4 receptor activator for cognition and sleep
This study tests whether prucalopride, a 5-HT4 receptor drug, can improve thinking and sleep in adults with low mood or major depressive disorder compared to a placebo.
-
Pre-visit Companion Brief: a primary care AI-assisted check for depression and anxiety
This pilot tests an AI-powered pre-visit assessment that creates a concise Companion Brief for clinicians to help identify depression and anxiety during routine primary care.
-
Medically tailored groceries to help depression in people with food insecurity
This trial tests whether giving medically tailored groceries for six months can reduce depressive symptoms in adults who have depression and struggle with access to food.
-
Health and Work Ability After Inpatient Treatment for Stress-Related Disorders: Follow-Up of the HARMODI Cohort
This study follows people who had inpatient treatment for stress-related disorders to see how their health and ability to work change over the next three years and what factors help them return to work.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.